> [...] there may be a common underlying structure between biology and information science - an isomorphic mapping between the two - hence the name of the company. Biology is likely far too complex and messy to ever be encapsulated as a simple set of neat mathematical equations. ...uses a neatly-defined mathematical term to name the company, then rejects the idea of neat mathematics in practice.
Isomorphic Labs: Reimagining drug discovery with an AI-first approach
11–20 of 26 posts
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#12Earlier quoted context omitted.
I believe there is a lot of internal politics and dynamics playing here. If you are Demis Hassabis and want to lead this new initiative: - Why would you want to report to the CEO of another subsidiary instead of spinning-off another entity within the Alphabet conglomerate? - You can let the DeepMind team focus in their original areas of expertise. - You will have a new (and $$$$) budget to hire computational biology…
Does anyone have a good idea what Verily or Calico actually do, or have done?
Calico does basic life science research and publishes it, https://calicolabs.com/publications and also has private partnerships. They are pretty secretive so it's hard to know but most of the research is about using mouse models to understand fundamental details of aging biology, the long game being to make Larry Page live forever.
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#13Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#14> [...] there may be a common underlying structure between biology and information science - an isomorphic mapping between the two - hence the name of the company. Biology is likely far too complex and messy to ever be encapsulated as a simple set of neat mathematical equations. ...uses a neatly-defined mathematical term to name the company, then rejects the idea of neat mathematics in practice.
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#15Can someone explain to me why this should be an entirely new company (subsidiary) rather than folding DeepMind's capabilities into Verily and Calico? Are these different groups siloed from one another within Google?
I believe there is a lot of internal politics and dynamics playing here. If you are Demis Hassabis and want to lead this new initiative: - Why would you want to report to the CEO of another subsidiary instead of spinning-off another entity within the Alphabet conglomerate? - You can let the DeepMind team focus in their original areas of expertise. - You will have a new (and $$$$) budget to hire computational biology…
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#16Was alalphafold2 that big of a landmark in application sense? I realize the protein folding problem is a hard and important one. But I didn't realize this result had immediate practical application. Will they just be consulting pharmas? Patienting proteins and such?
Personally I’m hoping that someone smarter than me figures out how to displace existing catalysts like platinum and palladium. Seems like it could be a pretty penny and some positive environmental impact to boot.
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#17Was alalphafold2 that big of a landmark in application sense? I realize the protein folding problem is a hard and important one. But I didn't realize this result had immediate practical application. Will they just be consulting pharmas? Patienting proteins and such?
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#18Was alalphafold2 that big of a landmark in application sense? I realize the protein folding problem is a hard and important one. But I didn't realize this result had immediate practical application. Will they just be consulting pharmas? Patienting proteins and such?
I think it could be Nobel Prize worthy. Protein’s structure often determines its effect as a catalyst. So to map the DNA to the 2nd order outcomes seems like it could be the missing ingredient to controlling the properties of cells. Personally I’m hoping that someone smarter than me figures out how to displace existing catalysts like platinum and palladium. Seems like it could be a pretty penny and some positive envi…
Re: Isomorphic Labs: Reimagining drug discovery with an AI-first approach
#19Was alalphafold2 that big of a landmark in application sense? I realize the protein folding problem is a hard and important one. But I didn't realize this result had immediate practical application. Will they just be consulting pharmas? Patienting proteins and such?
I think it could be Nobel Prize worthy. Protein’s structure often determines its effect as a catalyst. So to map the DNA to the 2nd order outcomes seems like it could be the missing ingredient to controlling the properties of cells. Personally I’m hoping that someone smarter than me figures out how to displace existing catalysts like platinum and palladium. Seems like it could be a pretty penny and some positive envi…